- Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
-
Shimizu H, Fujii T, Hibiya S, Motobayashi M, Suzuki K, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M
- KMID: 2512107
- Intest Res.
- 2021 Jan;19(1):115-118.
- doi: 10.5217/ir.2020.00030
-
- CITED
-
- Close
- SHARE
-
- Close
- Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
-
Yagisawa K, Kobayashi T, Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida M, Saito E, Nakano M, Matsubara H, Hisamatsu T, Hibi T
- KMID: 2504591
- Intest Res.
- 2020 Jul;18(3):343-344.
- doi: 10.5217/ir.2018.00078-c1
-
- CITED
-
- Close
- SHARE
-
- Close
- Tacrolimus for the Treatment of Ulcerative Colitis
-
Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M
- KMID: 2174466
- Intest Res.
- 2015 Jul;13(3):219-226.
- doi: 10.5217/ir.2015.13.3.219
Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy
-
Kawamoto A, Takenaka K, Hibiya S, Kitazume Y, Shimizu H, Fujii T, Saito E, Ohtsuka K, Okamoto R
- KMID: 2551279
- Intest Res.
- 2024 Jan;22(1):65-74.
- doi: 10.5217/ir.2023.00092
Background/Aims: Endoscopic activity confirmed by enteroscopy is associated with poor clinical outcome in Crohn’s disease (CD). We investigated which of the existing biomarkers best reflects endoscopic activity in CD patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
-
Okabayashi S, Kobayashi , Sujino T, Ozaki R, Umeda S, Toyonaga T, Saito E, Nakano M, Tablante M, Morinaga S, Hibi T
- KMID: 2396405
- Intest Res.
- 2017 Oct;15(4):535-539.
- doi: 10.5217/ir.2017.15.4.535
Extracolonic involvement of the gastrointestinal tract is extremely uncommon in ulcerative colitis (UC) and rarely found in the upper gastrointestinal tract or in postoperative cases since it typically responds to... -
- CITED
-
- Close
- SHARE
-
- Close
- Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
-
Okabayashi S, Kobayashi , Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T
- KMID: 2449963
- Intest Res.
- 2019 Apr;17(2):218-226.
- doi: 10.5217/ir.2018.00117
BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range... -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
-
Yagisawa K, Kobayashi , Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida , Saito E, Nakano M, Matsubara , Hisamatsu , Hibi T
- KMID: 2438447
- Intest Res.
- 2019 Jan;17(1):87-93.
- doi: 10.5217/ir.2018.00078
BACKGROUND/AIMS: Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The... -
- CITED
-
- Close
- SHARE
-
- Close
